Roche Holding AG

RHHVF

Drug Manufacturers - General · Healthcare

Price

$440.00

+10.48 (+2.44%)

Market Cap

$303.13B

Exchange

Other OTC

Winston Score

Winston is happy

A high-quality business with solid fundamentals.

Data as of Jul 28, 2026 · filings through Jun 30, 2026

Share count falling — buybacks

−6.6% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 860.0M (2021) → 803.0M (2025)

Roche is a Swiss healthcare company that makes medicines and medical tests. Its pharmaceutical division sells treatments for cancer, multiple sclerosis, and eye diseases — with well-known drugs like Herceptin, Avastin, and Ocrevus. Its diagnostics division makes lab equipment and tests used by hospitals and clinics worldwide, making Roche one of the largest diagnostics companies on the planet.

Roche earns money by selling prescription drugs directly to hospitals and healthcare systems, and by selling diagnostic instruments along with the consumable test kits they require. The company operates globally, with strong revenue from the US, Europe, and Japan, and generates over $50 billion in annual sales. Its deep pipeline of cancer drugs and its combined pharma-plus-diagnostics model give it a competitive edge, but a key risk is patent expiration on older blockbuster drugs, which opens the door to cheaper biosimilar competitors that can quickly erode sales.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

73.7%

Premium pricing power — 73.7% gross margin

Operating Margin

31.1%

Excellent — 31.1% operating margin

ROCE

14.6%

Good — 14.6% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-4.3%

Shrinking sales (-4.3% YoY)

EPS YoY

+29.5%

Earnings growing fast (29.5% YoY)

Earnings growing 25%+ a year. The compounder zone.

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

149%

Turns 149% of profit into real cash

FCF Margin

24.2%

Converts sales into free cash efficiently (24.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.97

Moderate — manageable debt (0.97)

Interest Cover

12.97x

Comfortably covers interest (13.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

28.7x

Growth-priced — P/E 28.7

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+9.1

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (28.7 → 19.6)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

2.72%

Moderate income — 2.72% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend Growth

+18.6%

Dividend growing fast (18.6% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial